

JOHNSTON, JAMES ▲

DOB: 09/21/1972	Age: 47	Specimen: DL504004W	Collected: 05/13/2020 12:15	Client #: 10175330
Sex: M	Fasting: N	Requisition: 0001910	Received: 05/14/2020 05:54	LUKNER, RALF B
Phone: (806) 440-2310		Report Status: FINAL / SEE REPORT	Reported: 05/16/2020 20:56	LUKNER MEDICAL CLINIC
Patient ID: 653				2545 PERRYTON PKWY STE 31 32
				PAMPA, TX 79065-2820
				Phone: (806) 329-3050
				Fax: (806) 419-1042

FASTING: NO


▲ LIPID PANEL, NONFASTING W/O TRIGLYCERIDES

FINAL

Lab: IG

CHOLESTEROL, TOTAL (2093-3)


Reference Range: <200 mg/dL



FINAL

HDL CHOLESTEROL (2085-9)

Reference Range: > OR = 40 mg/dL




FINAL

Reference range varies across results

CHOL/HDL-C RATIO (9830-1)


Reference Range: <5.0 (calc)



FINAL

▲ NON HDL CHOLESTEROL (43396-1)

Reference Range: <130 mg/dL (calc)



FINAL

For patients with diabetes plus 1 major ASCVD risk factor, treating to a non-HDL-C goal of <100 mg/dL (LDL-C of <70 mg/dL) is considered a therapeutic option.


▲ DIRECT LDL

FINAL

Lab: IG

▲ DIRECT LDL (18262-6)

Reference Range: <100 mg/dL



Greatly elevated Triglycerides values (>1200 mg/dL) interfere with the dLDL assay. As no Triglycerides testing was ordered, interpret results with caution.

Desirable range <100 mg/dL for primary prevention;
<70 mg/dL for patients with CHD or diabetic patients
with > or = 2 CHD risk factors.


▲ CBC (INCLUDES DIFF/PLT)

FINAL

Lab: IG


WHITE BLOOD CELL COUNT (6690-2)

Reference Range: 3.8-10.8 Thousand/uL




RED BLOOD CELL COUNT (789-8)

Reference Range: 4.20-5.80 Million/uL



HEMOGLOBIN (718-7)


Reference Range: 13.2-17.1 g/dL



▲ HEMATOCRIT (4544-3)


Reference Range: 38.5-50.0 %

FINAL

**MCV** (787-2)


Reference Range: 80.0-100.0 fL

FINAL

**MCH** (785-6)


Reference Range: 27.0-33.0 pg

FINAL

**MCHC** (786-4)


Reference Range: 32.0-36.0 g/dL

FINAL

**RDW** (788-0)

Reference Range: 11.0-15.0 %


FINAL



PLATELET COUNT (777-3)


Reference Range: 140-400 Thousand/uL

FINAL

**MPV (776-5)**


Reference Range: 7.5-12.5 fL

FINAL

**ABSOLUTE NEUTROPHILS (751-8)**


Reference Range: 1500-7800 cells/uL

FINAL

**▲ ABSOLUTE LYMPHOCYTES (731-0)**


Reference Range: 850-3900 cells/uL

FINAL

**ABSOLUTE MONOCYTES (742-7)**

Reference Range: 200-950 cells/uL


FINAL



ABSOLUTE EOSINOPHILS (711-2)


Reference Range: 15-500 cells/uL

FINAL

**ABSOLUTE BASOPHILS (704-7)**


Reference Range: 0-200 cells/uL

FINAL

**NEUTROPHILS (770-8)**

%

FINAL




Reference range varies across results

LYMPHOCYTES (736-9)

%

FINAL




Reference range varies across results

MONOCYTES (5905-5)

%

FINAL




Reference range varies across results

EOSINOPHILS (713-8)

%

FINAL



Reference range varies across results


BASOPHILS (706-2)

%

0.5

FINAL

From 04/09/2019 To 05/14/2020



Reference range varies across results

▲ VITAMIN D,25-OH,TOTAL,IA

FINAL

Lab: IG


▲ VITAMIN D,25-OH,TOTAL,IA (1989-3)

Reference Range: 30-100 ng/mL

27

FINAL

From 04/28/2019 To 05/14/2020



Vitamin D Status 25-OH Vitamin D:

Deficiency: <20 ng/mL

Insufficiency: 20 - 29 ng/mL

Optimal: > or = 30 ng/mL

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssured(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

COMMENT

No Historical Data

FINAL

See Note 1

Note 1

For additional information, please refer to <http://education.QuestDiagnostics.com/faq/FAQ199> (This link is being provided for informational/educational purposes only.)


▲ TESTOSTERONE, FREE (DIALYSIS) AND TOTAL,MS

FINAL

Lab: Z3E

▲ TESTOSTERONE, TOTAL, MS (2986-8)

Reference Range: 250-1100 ng/dL



FINAL

Men with clinically significant hypogonadal symptoms and testosterone values repeatedly in the range

(Note)

For additional information, please refer to


<http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMS>

(This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by medfusion. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE (2991-8)

Reference Range: 35.0-155.0 pg/mL



FINAL

(Note)

This test was developed and its analytical performance characteristics have been determined by medfusion. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

MDF

med fusion

2501 South State Highway 121, Suite 1100

Lewisville TX 75067

972-966-7300

Benton R Middleman, MD


COMPREHENSIVE METABOLIC PANEL

FINAL

Lab: IG

GLUCOSE (2345-7)

Reference Range: 65-139 mg/dL




FINAL

Non-fasting reference interval

UREA NITROGEN (BUN) (3094-0)


Reference Range: 7-25 mg/dL

FINAL

**CREATININE** (2160-0)


Reference Range: 0.60-1.35 mg/dL

FINAL

**eGFR NON-AFR. AMERICAN** (77147-7)


Reference Range: > OR = 60 mL/min/1.73m2

FINAL

**eGFR AFRICAN AMERICAN** (48643-1)


Reference Range: > OR = 60 mL/min/1.73m2

FINAL

**BUN/CREATININE RATIO** (3097-3)

Reference Range: 6-22 (calc)


FINAL

NOT APPLICABLE

SODIUM (2951-2)


Reference Range: 135-146 mmol/L

FINAL

**POTASSIUM** (2823-3)


Reference Range: 3.5-5.3 mmol/L

FINAL

**CHLORIDE** (2075-0)


Reference Range: 98-110 mmol/L

FINAL

**CARBON DIOXIDE** (2028-9)


Reference Range: 20-32 mmol/L

FINAL

**CALCIUM** (17861-6)

Reference Range: 8.6-10.3 mg/dL


FINAL



PROTEIN, TOTAL (2885-2)


Reference Range: 6.1-8.1 g/dL

FINAL

**ALBUMIN** (1751-7)


Reference Range: 3.6-5.1 g/dL

FINAL

**GLOBULIN** (10834-0)


Reference Range: 1.9-3.7 g/dL (calc)

FINAL

**ALBUMIN/GLOBULIN RATIO** (1759-0)


Reference Range: 1.0-2.5 (calc)

FINAL

**BILIRUBIN, TOTAL** (1975-2)

Reference Range: 0.2-1.2 mg/dL


FINAL



ALKALINE PHOSPHATASE (6768-6)

FINAL

Reference Range: 36-130 U/L




Reference range varies across results

AST (1920-8)


FINAL

Reference Range: 10-40 U/L

**ALT (1742-6)**

FINAL

Reference Range: 9-46 U/L

**T4, TOTAL (THYROXINE)**


FINAL

Lab: EZ

T4, TOTAL (THYROXINE) (3026-2)

FINAL

Reference Range: 4.8-10.4 mcg/dL



Conversion factor: 1 mcg/dL = 12.9 nmol/L

HEMOGLOBIN A1c W/eAG WITH REFLEX TO GLYCOMARK®


FINAL

Lab: IG

HEMOGLOBIN A1c (4548-4)

FINAL

Reference Range: <5.7 % of total Hgb



For the purpose of screening for the presence of diabetes:

<5.7% Consistent with the absence of diabetes
5.7-6.4% Consistent with increased risk for diabetes (prediabetes)
> or =6.5% Consistent with diabetes

This assay result is consistent with a decreased risk of diabetes.

Currently, no consensus exists regarding use of hemoglobin A1c for diagnosis of diabetes in children.

According to American Diabetes Association (ADA) guidelines, hemoglobin A1c <7.0% represents optimal control in non-pregnant diabetic patients. Different metrics may apply to specific patient populations. Standards of Medical Care in Diabetes(ADA).

eAG (mg/dL) (27353-2)**111**

FINAL

(calc)

*No Historical Data***eAG (mmol/L) (53553-4)****6.2**

FINAL

(calc)

*No Historical Data***SARS CoV 2 SEROLOGY (COVID 19) AB (IGG), IA**

FINAL

Lab: IG

SARS CoV 2 AB IGG (94563-4)**NEGATIVE**

FINAL

No Historical Data

Reference range: Negative

This test is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus by molecular testing present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. This test should not be used to diagnose acute SARS-CoV-2 infection. If acute infection is suspected, direct testing by molecular methods for SARS-CoV-2 is necessary. False positive results for the test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

Please review the "Fact Sheets" available for health care providers and patients using the following websites:
QuestDiagnostics.com/home/Covid-19/HCP/antibody/fact-sheet2
QuestDiagnostics.com/home/Covid-19/Patients/antibody/fact-sheet2

This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by authorized laboratories. The FDA authorized labeling is available on the Quest Diagnostics website: www.QuestDiagnostics.com/Covid19.

For additional information please refer to <http://education.questdiagnostics.com/faq/FAQ219>
(This link is being provided for informational/educational purposes only.)


THYROID PEROXIDASE ANTIBODIES

FINAL

Lab: IG

THYROID PEROXIDASE ANTIBODIES (8099-4)

Reference Range: <9 IU/mL



FINAL


VITAMIN B12

FINAL

Lab: IG

VITAMIN B12 (2132-9)

Reference Range: 200-1100 pg/mL



FINAL

ESTRADIOL

FINAL

Lab: IG

JOHNSTON,JAMES (DL504004W)


13 / 15

7/20/20

ESTRADIOL (2243-4)

FINAL

Reference Range: < OR = 39 pg/mL



Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

T3, FREE


FINAL

Lab: IG

T3, FREE (3051-0)

FINAL

Reference Range: 2.3-4.2 pg/mL

**TSH W/REFLEX TO FT4**


FINAL

Lab: IG

TSH W/REFLEX TO FT4 (3016-3)

FINAL

Reference Range: 0.40-4.50 mIU/L

**Performing Sites**

EZ Quest Diagnostics/Nichols SJC-San Juan Capistrano., 33608 Ortega Hwy, San Juan Capistrano, CA 92675-2042 Laboratory Director: Irina Maramica MD,PhD,MBA

IG Quest Diagnostics-Dallas Lab, 4770 Regent Blvd, Irving, TX 75063-2445 Laboratory Director: Dr. Robert L Breckenridge







Z3E MedFusion-MedFusion, 2501 South State Highway 121, Suite 1100, Lewisville, TX 75067-8188 Laboratory Director: Benton R Middleman MD

Key

JOHNSTON,JAMES (DL504004W)

14 / 15

7/20/20

 Priority Out of Range  Out of Range  Pending Result  Preliminary Result  Final Result  Reissued Result

Note: Data displayed only for results that meet strict identification matching. Historical result view may vary based on corrected or updated patient demographics. The reference range displayed may vary due to potential changes in laboratory testing methods. Please refer to the published reference range on each lab report.

Quest, Quest Diagnostics, the associated logo, Nichols Institute, Interactive Insights and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third party marks - '®' and '™' - are the property of their respective owners. Privacy policy can be found at: <http://questdiagnostics.com/home/privacy-policy/online-privacy.html>. © 2020 Quest Diagnostics Incorporated. All rights reserved.